Leerink Partners analyst Mani Foroohar has maintained their bullish stance on FDMT stock, giving a Buy rating on August 1.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mani Foroohar has given his Buy rating due to a combination of factors related to the promising results from 4D Molecular Therapeutics’ recent clinical trial. The Phase 2 SPECTRA trial for 4D-150 in diabetic macular edema (DME) showed a strong safety profile, with no intraocular inflammation and normal intraocular pressure across the patient group. The trial’s efficacy results were consistent with previous updates, showing significant improvements in visual acuity and reductions in central subfield thickness, along with a notable decrease in the need for supplemental injections.
The positive data from the trial, including the fact that a significant portion of patients required fewer injections, supports the potential of 4D-150 in treating DME and possibly other ophthalmologic conditions. Furthermore, the alignment with the European Medicines Agency on a single Phase 3 registrational trial, alongside ongoing discussions about potential partnerships outside the United States, adds to the commercial potential and strategic value of the therapy. These factors collectively underpin Foroohar’s optimistic outlook and Buy rating for FDMT.
In another report released on August 1, H.C. Wainwright also reiterated a Buy rating on the stock with a $36.00 price target.